ESMO 2019

September 27 - October 1

Barcelona, Spain

Booth #303

SEE OUR POSTER PRESENTATIONS

Saturday 28 September

Poster Presentation 1560P | Disease monitoring of EGFR mutation-positive NSCLC patients via circulating tumor DNA

Poster Presentation 1559P | An exploratory analysis of on-treatment ctDNA measurement as a potential surrogate for overall survival for atezolizumab benefit in the OAK Study

Poster Presentation 1744P | Mutational profiling of tumor tissue and sequential plasma illustrates emergent clones during treatment in late stage small cell lung cancer (SCLC)

Monday 30 September

Poster Presentation 1416P | Enhanced Access to EGFR Molecular Testing in NSCLC using a Cell-Free DNA Tube for Liquid Biopsy

VISIT OUR BOOTH

Come visit booth #303 to hear more about our Diagnostics Oncology Solutions

AVENIO NGS Assays for Clinical Research*

Liquid biopsy and tumor tissue assays for comprehensive genomic profiling, surveillance & monitoring. AVENIO NGS assays are for Research Use Only. Not for Use in Diagnostic Procedures.

*Research Use Only. Not for use in diagnostic procedures.

cobas^® EGFR Mutation Test v2

The only FDA-approved diagnostic test for NSCLC using liquid biopsy. Companion diagnostic for Tarceva^{^®}(erlotinib), IRESSA^{^®} (gefitinib) & TAGRISSO^{^®} (osimertinib)

Companion Diagnostics

In collaboration with leading pharmaceutical companies, we identify and develop innovative predictive diagnostics to target those patients who are more likely to respond to specific therapies.

The global partner of choice for companion diagnostics, we help to advance Personalized Healthcare by delivering diagnostic confidence through a broad menu of high medical value predictive assays. Our standardized, fully-automated and easy-to-use solutions enable rapid turnaround time, empowering physicians to make the right patient decisions more quickly.

Digital Pathology solution

The Roche Digital Pathology solution combines innovative hardware, software and VENTANA Companion Algorithm image analysis software, and works in integrated harmony with the full Roche diagnostic portfolio for an end-to-end experience.

NAVIFY^® Mutation Profiler**

A clinical NGS reporting solution that can help labs accurately and efficiently interpret the clinical significance of mutations, empowering clinicians to deliver more personalized healthcare.

^**Not yet commercially available in the US

NAVIFY^® Tumor Board

Developed as a result of the collaboration between Roche and GE Healthcare, NAVIFY Tumor Board is a cloud-based workflow product that securely integrates and displays relevant aggregated data into a single, holistic patient dashboard for oncology care teams to review, align and decide on the optimal treatment for the patient.

VENTANA HER2 Dual ISH DNA Probe Cocktail CE IVD

Optimized with new oligo probes, the VENTANA HER2 Dual ISH assay delivers clear, confident reads.

The new VENTANA HER2 Dual ISH DNA Probe Cocktail assay is a fully automated, ready-to-use brightfield solution for determining HER2 gene status. VENTANA HER2 Dual ISH helps identify breast and gastric cancer patients eligible for treatment with HER2-targeted personalized therapies.

VENTANA ROS1 (SP384) Rabbit Monoclonal Primary Antibody

The new VENTANA ROS1 assay is the first IVD IHC ROS1 test on the market. This pre-optimized, ready-to-use assay is highly correlated to FISH break-apart status, giving pathologists greater confidence when sending cases out for confirmatory testing. Guidelines from the College of American Pathologists and the National Comprehensive Cancer Network recommend ROS1 testing for confirmed lung adenocarcinoma cases.

VENTANA, AVENIO, BENCHMARK, COBAS, NAVIFY and the VENTANA logo are trademarks of Roche. All other product names and trademarks are the property of their respective owners.